#FDA approval

New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.

Though seldom malignant, tenosynovial giant cell tumors can damage joints and tendons.

The androgen receptor inhibitor delayed cancer metastasis in a late-stage clinical trial.

pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.

First nuclear export inhibitor gets the nod for patients lacking treatment options.

Darzalex in combination with lenalidomide and dexamethasone is for people who are ineligible for an autologous stem cell transplant.

New immunotherapy option approved for uncommon, aggressive type of lung cancer.

The Food and Drug Administration may approve the next site-agnostic treatment in August.

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.

Eighty percent of medications that receive accelerated approval don’t extend overall survival.

Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.

Piqray plus Faslodex prolonged progression-free survival for metastatic breast cancer patients with PIK3CA gene mutation.